International Centre for Genetic Engineering & Biotechnology, Recombinant Gene Products Group, PO Box 10504, Aruna Asaf Ali Marg, New Delhi-110067, India.
Expert Opin Ther Pat. 2010 Jun;20(6):819-35. doi: 10.1517/13543771003767476.
Dengue is a significant public health problem transcending geographical boundaries to place nearly 50% of the global population at risk. A vaccine to prevent dengue is an unmet need that should be addressed urgently.
A brief introduction to dengue and a detailed review of the classical and modern approaches being undertaken currently to develop dengue vaccines described in recent patent literature, highlighting the inherent hurdles and challenges.
An understanding of the approaches being deployed to develop multiple viral and non-viral vaccine candidates and an appreciation of the complexity of developing dengue vaccines.
Live viral vaccines, which have advanced to clinical trials, have revealed new challenges, emphasizing the need to pursue non-viral alternatives simultaneously.
登革热是一个重大的公共卫生问题,跨越地理界限,使近 50%的全球人口面临风险。预防登革热的疫苗是一个未满足的需求,应紧急解决。
简要介绍登革热,并详细回顾目前为开发登革热疫苗而采用的经典和现代方法,这些方法在最近的专利文献中有描述,强调了内在的障碍和挑战。
了解为开发多种病毒和非病毒疫苗候选物而部署的方法,并认识到开发登革热疫苗的复杂性。
已进入临床试验的活病毒疫苗揭示了新的挑战,强调需要同时寻求非病毒替代方案。